Analysis of:
Ranbaxy Gains Approval To Manufacture And Market Carvedilol Tablets In The U.S. Market (www.medicalnewstoday.com)
Carvidolol is an excellent drug indicated for the treatment of CHF Very Expensive drug on restricted formulary by many HMOs A good news to many physicians who were restricted in using this drug.
Analysis of:
Novartis's Tekturna shows promise in heart failure (www.reuters.com)
RAAS inhibition at many levels is an exciting idea! New Class of antihypertensive is welcomed by many physicians who struggle with BP controll in many of their HTN patients.
Analysis of:
Potential safety issue identified in ongoing phase 2 clinical study of HCV-796 (www.pipelinereview.com)
High prevalence of hepatitis C virus infection worldwide! Most therapies available have limited success esp. genotype 1 HCV genotype 1 most prevalent in US Most treatments are toxic Combination therapy need to devised
Analysis of:
Affymax(R) Announces Phase 3 Development Plan for Hematide(TM) (www.pipelinereview.com)
Many of the novel esa's were in development prior to the choir study results and FDA black box label. They probably would have thought twice about investment into an agent that has a main selling point of "long half-life". This implies that he could potentially be more difficult to titrate...
Analysis of:
New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis ) (www.therapeuticsdaily.com)
Levocertirizine is the active enantiomer of the well-known antihistamine Zyrtec. Both Zyrtic and Xyzal, undergo a rapid and complete uptake in the GI tract and then metabolized to a very limited extent and have a high renal clearance. Xyzal does not have any advantage over Zyrtec
Analysis of:
Drugstore Clinics Spread, and Scrutiny Grows (www.nytimes.com)
Delf Referal Lack of continuity of care However, Cheaper and Faster, more easlit accessible. It takes one big mistake to shut them down. Diagnosis is not that simple. After all not all Flu like symptoms are Flu!!!!!
Analysis of:
FDA Panel to Discuss (online.wsj.com)
Possible more restriction on the use of ESA agen
Analysis of:
FDA Gives Go-Ahead to Once-Daily Valsartan-Amlodipine Combination Pill for Hypertension (www.medscape.com)
ExForge is a product that we in the hypertension business are very anxious to have available. Combination tablets have been increasing in sales very dramatically in the past few years and will soon overtake, in my opinion, single agents. Lotrel led the way toward combinations that do not include a diuretic...
Analysis of:
King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For 24-hour Blood Pressure Control (pharmalive.com)
ACE inhibitors have become the first line drugs in treatment of hypertension. One major side-effect, especially if there is renal dysfunction is the development of hyperkalemia. The combination of Altace with hydrochlorthiazide will help in diminishing this problem. It would also help if there was a...
Analysis of:
Early Results Of The CellCept(R) Spare The Nephron Study Examine Kidney Function (www.medicalnewstoday.com)
Interim results from "Spare the Nephron Trial" demosntrate improved outcomes with Rapamycin based immunosupression compared with Calcinuerin based therapy. If the results hold up the trial may precipitate a shift away from the use of cyclospoin and tacrolimus based therapy in favor...